Laboratorios Farmaceuticos Rovi, S.A./ADR
LABFF$4.63B
Mid CapNASDAQBiotechnology🇺🇸North America2.2K employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
LABFF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DMMET-01 | Phase 3 | Diabetes Type 2 | - | - |
Nimotuzumab | Phase 2 | Diffuse Intrinsic Brainstem Gliomas | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply